Organon Pharma Indonesia Tbk PT
IDX:SCPI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its Industry Average (3.7), the stock would be worth Rp-265 149.63 (1 014% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.4 | Rp29 000 |
0%
|
| Industry Average | 3.7 | Rp-265 149.63 |
-1 014%
|
| Country Average | 3.7 | Rp-265 149.63 |
-1 014%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| ID |
O
|
Organon Pharma Indonesia Tbk PT
IDX:SCPI
|
104.4B IDR | -0.4 | 0.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 15.5 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 8.8 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.3 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 6.3 | 27.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 7.2 | 20.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 5.8 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 5 | 11.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 4.2 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 4.2 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.8 |
| Median | 3.7 |
| 70th Percentile | 6.7 |
| Max | 2 220 102.4 |
Other Multiples
Organon Pharma Indonesia Tbk PT
Glance View
PT Organon Pharma Indonesia Tbk engages in the development, manufacture, and distribution of pharmaceutical products. The company is headquartered in Jakarta Pusat, Dki Jakarta. The firm is engaged in the processing, packaging and development of pharmaceutical products for human and animal consumption, toiletries, cosmetics, household and related products. The firm is also engaged in importing of raw materials, finished goods and providing business and management consultancy services. The Company’s segments include Pharmaceutical Manufacturing and commercial. For women's health, the Company develops product specifically for women, including contraception, fertility, pregnancy management, perinatal diseases and other diseases. The Company’s subsidiaries include Organon LLC, PT Merck Sharp & Dohme Indonesia, Merck Sharp & Dohme Corp and Merck Sharp & Dohme Asia.
